Literature DB >> 18602932

The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum.

Kelly E Bosse1, Emily M Jutkiewicz, Margaret E Gnegy, John R Traynor.   

Abstract

The highly selective delta opioid agonist, SNC80, elicits dopamine-related behaviors including locomotor stimulation and conditioned place-preference. In contrast, it has been reported that SNC80 fails to promote dopamine efflux from the striatum of freely moving rats. However, SNC80 does enhance behavioral responses to the stimulants, amphetamine and cocaine, suggesting an interaction between delta opioids and psychostimulants. Since the increase in locomotor activity elicited by amphetamine and related stimulants acting at the dopamine transporter is associated with increases in extracellular concentrations of dopamine within the striatum, we hypothesized that SNC80 enhances this activity by potentiating the overflow of dopamine through the transporter. To test this hypothesis, striatal preparations from Sprague Dawley rats were assayed for dopamine efflux in response to amphetamine challenge. SNC80 was given either in vivo or in vitro directly to rat striatal tissue, prior to in vitro amphetamine challenge. Both in vivo and in vitro administration of SNC80 enhanced amphetamine-mediated dopamine efflux in a concentration- and time-dependent manner. However, SNC80 in either treatment paradigm produced no stimulation of dopamine efflux in the absence of amphetamine. The effect of SNC80 on amphetamine-mediated dopamine overflow, but not the effect of amphetamine alone, was blocked by the delta selective antagonist, naltrindole and was also observed with other delta agonists. The results of this study demonstrate that even though SNC80 does not stimulate dopamine efflux alone, it is able to augment amphetamine-mediated dopamine efflux through a delta opioid receptor mediated action locally in the striatum.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602932      PMCID: PMC2659683          DOI: 10.1016/j.neuropharm.2008.06.017

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  42 in total

1.  Different regulation of human delta-opioid receptors by SNC-80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and endogenous enkephalins.

Authors:  I Lecoq; N Marie; Ph Jauzac; S Allouche
Journal:  J Pharmacol Exp Ther       Date:  2004-04-21       Impact factor: 4.030

2.  The delta agonists DPDPE and deltorphin II recruit predominantly mu receptors to produce thermal analgesia: a parallel study of mu, delta and combinatorial opioid receptor knockout mice.

Authors:  Grégory Scherrer; Katia Befort; Candice Contet; Jérôme Becker; Audrey Matifas; Brigitte L Kieffer
Journal:  Eur J Neurosci       Date:  2004-04       Impact factor: 3.386

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  Further evidence for a role of delta-opiate receptors in the presynaptic regulation of newly synthesized dopamine release.

Authors:  F Petit; M Hamon; M C Fournie-Zaluski; B P Roques; J Glowinski
Journal:  Eur J Pharmacol       Date:  1986-07-15       Impact factor: 4.432

5.  Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats.

Authors:  Daniel C Broom; Emily M Jutkiewicz; John E Folk; John R Traynor; Kenner C Rice; James H Woods
Journal:  Neuropsychopharmacology       Date:  2002-06       Impact factor: 7.853

6.  Kappa- and delta-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release.

Authors:  A H Mulder; G Wardeh; F Hogenboom; A L Frankhuyzen
Journal:  Nature       Date:  1984 Mar 15-21       Impact factor: 49.962

7.  A rapid method for the regional dissection of the rat brain.

Authors:  T G Heffner; J A Hartman; L S Seiden
Journal:  Pharmacol Biochem Behav       Date:  1980-09       Impact factor: 3.533

8.  The delta-opioid receptor agonist SNC80 [(+)-4-[alpha(R)-alpha-[(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl]-(3-methoxybenzyl)-N,N-diethylbenzamide] synergistically enhances the locomotor-activating effects of some psychomotor stimulants, but not direct dopamine agonists, in rats.

Authors:  Emily M Jutkiewicz; Michelle G Baladi; John E Folk; Kenner C Rice; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2007-11-06       Impact factor: 4.030

9.  Self-injection of amphetamine directly into the brain.

Authors:  B G Hoebel; A P Monaco; L Hernandez; E F Aulisi; B G Stanley; L Lenard
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Modulation of dopamine release in rat striatal slices by delta opiate agonists.

Authors:  C Lubetzki; M F Chesselet; J Glowinski
Journal:  J Pharmacol Exp Ther       Date:  1982-08       Impact factor: 4.030

View more
  8 in total

1.  Endogenous opioids as physiological antidepressants: complementary role of δ receptors and dopamine.

Authors:  Emily M Jutkiewicz; Bernard P Roques
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

2.  Asymmetric generalization and interaction profiles in rhesus monkeys discriminating intravenous cocaine or intravenous heroin from vehicle.

Authors:  Donna M Platt; James K Rowlett; Roger D Spealman
Journal:  J Pharmacol Exp Ther       Date:  2009-12-04       Impact factor: 4.030

Review 3.  The delta opioid receptor tool box.

Authors:  Ana Vicente-Sanchez; Laura Segura; Amynah A Pradhan
Journal:  Neuroscience       Date:  2016-06-24       Impact factor: 3.590

4.  Antidepressant-like and anxiolytic-like effects following activation of the μ-δ opioid receptor heteromer in the nucleus accumbens.

Authors:  N Kabli; T Nguyen; G Balboni; B F O'Dowd; S R George
Journal:  Mol Psychiatry       Date:  2013-09-24       Impact factor: 15.992

5.  Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism.

Authors:  Kelly E Bosse; Emily M Jutkiewicz; Kristin N Schultz-Kuszak; Omar S Mabrouk; Robert T Kennedy; Margaret E Gnegy; John R Traynor
Journal:  Neuropharmacology       Date:  2013-09-10       Impact factor: 5.250

Review 6.  The role of enkephalinergic systems in substance use disorders.

Authors:  Lauren G Rysztak; Emily M Jutkiewicz
Journal:  Front Syst Neurosci       Date:  2022-08-05

7.  Contrasting changes in extracellular dopamine and glutamate along the rostrocaudal axis of the anterior cingulate cortex of the rat following an acute d-amphetamine or dopamine challenge.

Authors:  Elizabeth S Ash; David J Heal; S Clare Stanford
Journal:  Neuropharmacology       Date:  2014-04-18       Impact factor: 5.250

Review 8.  Enkephalin as a Pivotal Player in Neuroadaptations Related to Psychostimulant Addiction.

Authors:  Bethania Mongi-Bragato; María P Avalos; Andrea S Guzmán; Flavia A Bollati; Liliana M Cancela
Journal:  Front Psychiatry       Date:  2018-05-28       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.